• Cadence Pharmaceuticals Inc., of San Diego, said underwriters exercised their overallotment option in full to purchase an additional 900,000 shares of common stock in connection with the $48.5 million initial public offering priced last month. With the overallotments, the offering brought in net proceeds of $57.8 million, which will be used to support its two Phase III products: an intravenous form of acetaminophen and Omigard (omiganan pentahydrochloride) gel. Merrill Lynch & Co. acted as sole book-running manager and Deutsche Bank Securities acted as co-lead manager. (See BioWorld Today, Oct. 26, 2006.)

• Dendreon Corp., of Seattle, submitted the final portion of its rolling biologics license application for Provenge (sipuleucel-T) started in August. Dendreon is seeking marketing approval for Provenge in asymptomatic, metastatic, androgen-independent prostate cancer, and is asking for a priority review that would call for FDA action within six months. (See BioWorld Today, Aug. 25, 2006.)

• Medarex Inc., of Princeton, N.J., said it expects an undisclosed milestone payment from its licensing partner, Thousand Oaks, Calif.-based Amgen Inc. for the advancement into the clinic of an antibody developed using Medarex's UltiMAb technology. That antibody is the fourth to emerge in the companies' collaboration, and Medarex could receive future milestone payments and royalties if the candidate progresses through clinical development and to the market.

• MorphoSys AG, of Munich, Germany, said its partner, Boehringer Ingelheim GmbH, of Ingelheim, Germany, exercised its option for optimizing a therapeutic HuCAL antibody and acquired an exclusive license. Under the terms, MorphoSys will optimize the antibody, which is directed against a cancer disease-related target molecule, in accordance with its partners' requirements and will receive additional research payments. Specific terms were not disclosed. The companies have been collaborating since 2003, starting with two therapeutic antibody projects against inflammatory and cardiovascular diseases.

• Spectrum Pharmaceuticals Inc., of Irvine, Calif., said it will receive a $5 million milestone payment under its agreement with Woodcliff Lake, N.J.-based Par Pharmaceuticals Inc. for sumatriptan injection, a migraine therapy marketed as Imitrex by London-based GlaxoSmithKline plc.

• SR Pharma plc, of London, completed initial toxicology studies for its RNAi product candidate, Atu027, confirming that there was no problem at the site of injection. Atu027 is a reconstituted lyophilized material tested in repeated four-hour and 24-hour continuous intravenous infusions. SR anticipates beginning human studies next year.

• TmBioscience Corp., of Toronto, said its board initiated a process to explore strategic alternatives to enhance shareholder value, including the sale or merger of the company. The board established a special committee of directors to review, consider and analyze potential strategic opportunities, and retained the investment banking firms Leerink Swann & Co., of Boston, and Westwind Partners, of Toronto, as financial advisers.

No Comments